Clinical Trials
9 trialsNCT00795665 2020-05-12
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Phase 2 Completed
NCT01186406 2019-02-15
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Duke University
Phase 2 Terminated
NCT00003176 2018-06-27
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00004688 2015-03-25
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
FDA Office of Orphan Products Development
Phase 2 Completed
NCT00005081 2014-08-21
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
Duke University
Phase 2 Completed
NCT00003467 2013-06-20
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
Duke University
Phase 2 Completed
NCT00014573 2013-04-08
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00548938 2009-09-18
Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
Methodist Healthcare - Memphis
Phase 2 Terminated
NCT00283543 2007-10-31
Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma
Kentuckiana Cancer Institute
Phase 2 Unknown